Compare FRO & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRO | BLLN |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.6B |
| IPO Year | 1995 | 2025 |
| Metric | FRO | BLLN |
|---|---|---|
| Price | $43.84 | $97.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $37.67 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 1.9M | 801.1K |
| Earning Date | 05-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.85% | N/A |
| EPS Growth | N/A | ★ 103.40 |
| EPS | N/A | ★ 0.48 |
| Revenue | N/A | ★ $305,112,000.00 |
| Revenue This Year | N/A | $46.29 |
| Revenue Next Year | N/A | $30.14 |
| P/E Ratio | ★ $34.05 | $197.98 |
| Revenue Growth | N/A | ★ 99.97 |
| 52 Week Low | $19.87 | $61.96 |
| 52 Week High | $45.17 | $150.44 |
| Indicator | FRO | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 66.43 | 41.41 |
| Support Level | $36.37 | $81.73 |
| Resistance Level | N/A | $97.36 |
| Average True Range (ATR) | 1.33 | 5.88 |
| MACD | 0.41 | -1.35 |
| Stochastic Oscillator | 82.61 | 14.85 |
Frontline PLC is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.